Biotech Startups

1 investor

1 investor

Traphaco is a Vietnamese pharmaceutical company that produces traditional medicine and modern pharmaceuticals using contemporary technology and environmentally sustainable supply chains. The company serves healthcare communities and operates under principles linking economic growth with environmental protection and social responsibility.

1 investor

Travere Therapeutics develops and delivers therapies for rare kidney and metabolic diseases, with a pipeline including potential first-in-class treatments for conditions such as classical homocystinuria and immune-mediated rare kidney diseases. The company also supports initiatives to improve diagnosis, access, and equity in rare disease care for patients and their families.

1 investor

Traverse provides health data solutions to pharmaceutical and biotech companies by connecting them with healthcare organizations and leveraging machine learning to generate insights from anonymized patient records. The platform supports evidence-based decision-making and improves patient outcomes while maintaining regulatory compliance.

1 investor

Travv develops AI-powered veterinary diagnostics, including digital pathology tools for the animal health industry. The company builds diagnostic technology aimed at advancing veterinary and anatomic pathology.

1 investor

Traws Pharma is a pharmaceutical company developing therapeutics, with a leadership focus spanning oncology, infectious disease, and medical science areas.

1 investor

Trears Biomarkers develops medical devices and biomarker platforms using earwax-based sampling to enable long-term monitoring of chronic conditions like metabolic syndrome and cardiovascular disease. The company operates at the intersection of clinical diagnostics and digital health, serving healthcare systems and clinical partners with non-invasive alternatives to point-in-time blood or saliva testing.

1 investor

Tree Flowers Solutions (TFS) researches, develops, and produces natural preservatives and tannins for the agri-food industry, with a focus on the beverage sector and particularly the wine industry. It offers extraction, water and solvent concentration, spray-drying, packaging, and freezing services, and works on natural ingredient and biobased coating projects with scientific and industry partners.

1 investor

TreeFrog develops C-Stem, a GMP-compliant technology platform for scalable production of cell therapies that optimizes yield and quality while minimizing cell damage. The platform serves biotech and cell therapy companies from early-stage research through commercial manufacturing.

1 investor

Treeline Biosciences is a drug discovery and development company focused on designing therapeutics for cancer patients. It combines laboratory research and clinical insight to guide its oncology-focused drug design.

1 investor

TRELEGY is a once-daily prescription inhaler used long-term to treat COPD (including chronic bronchitis and emphysema) and asthma in adults. It combines an inhaled corticosteroid, an anticholinergic, and a long-acting beta2-adrenergic agonist, and is not intended as a rescue inhaler.

1 investor

Trench Therapeutics develops live biotherapeutic products derived from research on the nasal microbiome to prevent and treat infectious and inflammatory diseases. Its approach aims to provide alternatives to antibiotic use and address antibiotic resistance.

1 investor

Tres Alchemix develops AI platforms that combine quantum-level chemical calculations with multi-omics models trained on curated biochemical and pharmacological data to predict how chemicals behave in the human body, including drug properties, chemical-protein interactions, and pharmacokinetics/pharmacodynamics. The company applies these technologies to AI-driven drug development and biological research questions.

1 investor

Trevena develops and commercializes innovative pharmaceutical therapies for central nervous system disorders. The company has an FDA-approved drug (OLINVYK) and multiple investigational candidates targeting migraine, opioid use disorder, and neuropathic pain.

1 investor

TriApex provides contract research organization (CRO) services supporting pharmaceutical and biologics development, including preclinical studies, clinical trial design, regulatory strategy, and post-market safety monitoring.

1 investor

Tridek-One Therapeutics develops bispecific antibodies that agonize the CD31 ITIM inhibitory checkpoint receptor to modulate immune cell activation for inflammatory and autoimmune diseases. Its lead program is a CD31×GPVI bispecific antibody for thromboinflammatory cardiovascular diseases, aiming to provide antithrombotic and anti-inflammatory effects while minimizing bleeding risk.

1 investor

Trident Bioscience develops software for protein design that uses computational models to identify candidate protein sequences and optimize them into gene libraries for rapid experimental testing. The platform aims to shorten the timeline for developing synthetic proteins.

1 investor

1 investor

Trillium Health Care Products is a contract manufacturer of prescription and over-the-counter pharmaceutical and consumer products for North American companies, based in Brockville, Ontario. With over 50 years of experience, it manufactures a range of medications and health products while maintaining FDA and Health Canada compliance.

1 investor

Trilobio builds lab automation systems designed for biologists to conduct experiments reliably and accessibly. The company develops tools to reduce manual workflows and human error in biological research, serving researchers across academic and commercial labs.

1 investor

TrioMed develops portable peritoneal dialysis systems for patients requiring renal replacement therapy at home or while traveling.

1 investor

TripleW converts food waste into high-value biomaterials for use in circular economy applications. The company produces lactic acid, ethyl lactate, and related lactate compounds in various grades.

1 investor

Trogenix develops precision gene therapies for cancer using its Odysseus platform and Synthetic Super-Enhancer (SSE) technology, engineered DNA elements activated only in diseased cell states to selectively target and kill tumour cells while activating the immune system. Its lead program, TGX-007, is a gene therapy for glioblastoma in a Phase I/II clinical trial, with potential applications in solid tumours and regenerative medicine.

1 investor